Predicting renal graft failure by sCD30 levels and de novo HLA antibodies at 1 year post-transplantation

详细信息	查看全文 | 推荐本文 |

• 作者：Dong Wang^a ; ¹ ; ² ; ^{wangdong1202@medmail.com.cn} ; Guojun Wu^b ; ¹ ; ³ ; Jinhua Chen^a ; ⁴ ; Ziqiang Yu^a ; ⁴ ; Weizhen Wu^a ; ⁴ ; Shunliang Yang^a ; ⁴ ; Jianming Tan^a ; ⁵ ; ^{doctortjm@yahoo.com}
• 关键词：HLA antibodies ; Soluble CD30 ; Renal transplantation ; Graft loss
• 刊名：Transplant Immunology
• 出版年：2012
• 期刊代码：251_09663274
• 类别：med
• 出版时间：June, 2012
• 卷：26
• 期：4
• 页码：235-239
• 文件大小：349 K

摘要

HLA antibodies and sCD30 levels were detected in the serum sampled from 620 renal graft recipients at 1 year post-transplantation, which were followed up for 5 years. Six-year graft and patient survivals were 81.6%and 91.0%. HLA antibodies were detected in 45 recipients (7.3%), of whom there were 14 cases with class I antibodies, 26 cases with class II, and 5 cases with both class I and II. Much more graft loss was record in recipients with HLA antibodies than those without antibodies (60%vs. 15.1%, p < 0.001). Significantly higher sCD30 levels were recorded in recipients suffering graft loss than the others (73.9 卤 48.8 U/mL vs. 37.3 卤 14.6 U/mL, p < 0.001). Compared with those with high sCD30 levels, recipients with low sCD30 levels (< 50 U/mL) had much better 6-year graft survival (92.4%vs. 46.6%, p < 0.001). Further statistical analysis showed that detrimental effect of de novo HLA antibodies and high sCD30 on graft survival was not only independent but also additive. Therefore, post-transplantation monitoring of HLA antibodies and sCD30 levels is necessary and recipients with elevated sCD30 level and/or de novo HLA antibody should be paid more attention in order to achieve better graft survival.